Systematic Profiling of Alternative Splicing Events in Ovarian Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Mar 25

PMID 33763357

Citations 4

Authors

Jia Liu

Dekang Lv

Xiaobin Wang

Ruicong Wang

Xiaodong Li

Affiliations

Soon will be listed here.

Abstract

Alternative splicing (AS) is significantly related to the development of tumor and the clinical outcome of patients. In this study, our aim was to systematically analyze the survival-related AS signal in ovarian serous cystadenocarcinoma (OV) and estimate its prognostic validity in 48,049 AS events out of 21,854 genes. We studied 1,429 AS events out of 1,125 genes, which were significantly related to the overall survival (OS) in patients with OV. We established alternative splicing features on the basis of seven AS events and constructed a new comprehensive prognostic model. Kaplan-Meier curve analysis showed that seven AS characteristics and comprehensive prognostic models could strongly stratify patients with ovarian cancer and make them distinctive prognosis. ROC analysis from 0.781 to 0.888 showed that these models were highly efficient in distinguishing patient survival. We also verified the prognostic characteristics of these models in a testing cohort. In addition, uni-variate and multivariate Cox analysis showed that these models were superior independent risk factors for OS in patients with OV. Interestingly, AS events and splicing factor (SFs) networks revealed an important link between these prognostic alternative splicing genes and splicing factors. We also found that the comprehensive prognosis model signature had higher prediction ability than the mRNA signature. In summary, our study provided a possible prognostic prediction model for patients with OV and revealed the splicing network between AS and SFs, which could be used as a potential predictor and therapeutic target for patients with OV.

Citing Articles

Alternative splicing in ovarian cancer.

Wei L, Li Y, Chen J, Wang Y, Wu J, Yang H Cell Commun Signal. 2024; 22(1):507.

PMID: 39425166 PMC: 11488268. DOI: 10.1186/s12964-024-01880-8.

Dysfunction of ATP7B Splicing Variant Caused by Enhanced Interaction With COMMD1 in Wilson Disease.

Zhou D, Zi H, Yang X, Li X, Li Y, Xu A Cell Mol Gastroenterol Hepatol. 2024; 19(2):101418.

PMID: 39389536 PMC: 11629249. DOI: 10.1016/j.jcmgh.2024.101418.

Differential expression of mRNA 3'-end isoforms in cervical and ovarian cancers.

Dioken D, Ozgul I, Koksal Bicakci G, Gol K, Can T, Erson-Bensan A Heliyon. 2023; 9(9):e20035.

PMID: 37810050 PMC: 10559779. DOI: 10.1016/j.heliyon.2023.e20035.

Multi-omics analysis of the Indian ovarian cancer cohort revealed histotype-specific mutation and gene expression patterns.

Mhatre A, Koroth J, Manjunath M, Kumar S S, Gawari R, Choudhary B Front Genet. 2023; 14:1102114.

PMID: 37091785 PMC: 10117685. DOI: 10.3389/fgene.2023.1102114.

References

Rylova S, Amalfitano A, Persaud-Sawin D, Guo W, Chang J, Jansen P . The CLN3 gene is a novel molecular target for cancer drug discovery. Cancer Res. 2002; 62(3):801-8. View

Takaya H, Nakai H, Takamatsu S, Mandai M, Matsumura N . Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma. Sci Rep. 2020; 10(1):2757. PMC: 7026096. DOI: 10.1038/s41598-020-59671-3. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View

Barata P, Rini B . Treatment of renal cell carcinoma: Current status and future directions. CA Cancer J Clin. 2017; 67(6):507-524. DOI: 10.3322/caac.21411. View

Koh C, Bezzi M, Low D, Ang W, Teo S, Gay F . MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis. Nature. 2015; 523(7558):96-100. DOI: 10.1038/nature14351. View

Zhou J, Yi Y, Wang C, Su C, Luo Y . Identification of a 3-mRNA signature as a novel potential prognostic biomarker in patients with ovarian serous cystadenocarcinoma in G2 and G3. Oncol Lett. 2019; 18(4):3545-3552. PMC: 6757305. DOI: 10.3892/ol.2019.10701. View

Li L, Gu H, Chen L, Zhu P, Zhao L, Wang Y . Integrative Network Analysis Reveals a MicroRNA-Based Signature for Prognosis Prediction of Epithelial Ovarian Cancer. Biomed Res Int. 2019; 2019:1056431. PMC: 6582839. DOI: 10.1155/2019/1056431. View

Sun L, Chen G, Sun A, Wang Z, Huang H, Gao Z . BAG2 Promotes Proliferation and Metastasis of Gastric Cancer via ERK1/2 Signaling and Partially Regulated by miR186. Front Oncol. 2020; 10:31. PMC: 7005010. DOI: 10.3389/fonc.2020.00031. View

Kobel M, Xu H, Bourne P, Spaulding B, Shih I, Mao T . IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Mod Pathol. 2009; 22(3):469-75. DOI: 10.1038/modpathol.2008.206. View

10.

Song H, Dicks E, Ramus S, Tyrer J, Intermaggio M, Hayward J . Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. J Clin Oncol. 2015; 33(26):2901-7. PMC: 4554751. DOI: 10.1200/JCO.2015.61.2408. View

11.

Lenzken S, Loffreda A, Barabino S . RNA splicing: a new player in the DNA damage response. Int J Cell Biol. 2013; 2013:153634. PMC: 3789447. DOI: 10.1155/2013/153634. View

12.

Mao D, Che J, Han S, Zhao H, Zhu Y, Zhu H . RNAi-mediated knockdown of the CLN3 gene inhibits proliferation and promotes apoptosis in drug-resistant ovarian cancer cells. Mol Med Rep. 2015; 12(5):6635-41. PMC: 4626189. DOI: 10.3892/mmr.2015.4238. View

13.

Hsu K, Shen M, Huang Y, Cheng Y, Lin S, Chow N . Overexpression of the RNA-binding proteins Lin28B and IGF2BP3 (IMP3) is associated with chemoresistance and poor disease outcome in ovarian cancer. Br J Cancer. 2015; 113(3):414-24. PMC: 4522643. DOI: 10.1038/bjc.2015.254. View

14.

Wang X, Ye M, Wu M, Fang H, Xiao B, Xie L . RNF213 suppresses carcinogenesis in glioblastoma by affecting MAPK/JNK signaling pathway. Clin Transl Oncol. 2020; 22(9):1506-1516. DOI: 10.1007/s12094-020-02286-x. View

15.

Enroth S, Berggrund M, Lycke M, Broberg J, Lundberg M, Assarsson E . High throughput proteomics identifies a high-accuracy 11 plasma protein biomarker signature for ovarian cancer. Commun Biol. 2019; 2:221. PMC: 6586828. DOI: 10.1038/s42003-019-0464-9. View

16.

Ju H, Zhao Q, Wang F, Lan P, Wang Z, Zuo Z . A circRNA signature predicts postoperative recurrence in stage II/III colon cancer. EMBO Mol Med. 2019; 11(10):e10168. PMC: 6783650. DOI: 10.15252/emmm.201810168. View

17.

Caminsky N, Mucaki E, Perri A, Lu R, Knoll J, Rogan P . Prioritizing Variants in Complete Hereditary Breast and Ovarian Cancer Genes in Patients Lacking Known BRCA Mutations. Hum Mutat. 2016; 37(7):640-52. DOI: 10.1002/humu.22972. View

18.

Shilo A, Ben Hur V, Denichenko P, Stein I, Pikarsky E, Rauch J . Splicing factor hnRNP A2 activates the Ras-MAPK-ERK pathway by controlling A-Raf splicing in hepatocellular carcinoma development. RNA. 2014; 20(4):505-15. PMC: 3964912. DOI: 10.1261/rna.042259.113. View

19.

Zhu J, Chen Z, Yong L . Systematic profiling of alternative splicing signature reveals prognostic predictor for ovarian cancer. Gynecol Oncol. 2017; 148(2):368-374. DOI: 10.1016/j.ygyno.2017.11.028. View

20.

Nilsen T, Graveley B . Expansion of the eukaryotic proteome by alternative splicing. Nature. 2010; 463(7280):457-63. PMC: 3443858. DOI: 10.1038/nature08909. View